Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how ...

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by ...

The elimination of the program addressing LGBTQ+ individuals on the national suicide hotline makes reaching specialized help ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared ...

A model that can estimate the need for pre-exposure prophylaxis (PrEP) in the US can help to clarify use patterns to address ...

A panelist discusses recent advancements in bispecific antibody therapies for relapsed/refractory multiple myeloma, ...

On April 10, 2025, leaders from Louisiana health systems convened in New Orleans to provide updates on the Healthy State ...

Several evidence-based health literacy resources may be beneficial in health plan settings to improve organizational health ...

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

From 1990 to 2021, the global burden of musculoskeletal disorders (MSDs) among postmenopausal women (PMW) grew significantly, and 2045 projections indicate this trend will continue, according to a ...

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

Eric Lander, MD, discussed the difficulty that clinicians and pharmacists face in getting insurance coverage for category 2B treatments in the National Comprehensive Cancer Network guidelines, which ...